Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Lipoxin A(4) encapsulated in PLGA microparticles accelerates wound healing of skin ulcers

Full text
Author(s):
Reis, Mouzarllem Barros ; Tartari Pereira, Priscilla Aparecida ; Caetano, Guilherme Ferreira ; Leite, Marcel Nani ; Galvao, Alyne Favero ; Garcia Paula-Silva, Francisco Wanderley ; Cipriani Frade, Marco Andrey ; Faccioli, Lucia Helena
Total Authors: 8
Document type: Journal article
Source: PLoS One; v. 12, n. 7 JUL 28 2017.
Web of Science Citations: 10
Abstract

Lipoxin A(4) (LXA(4)) is involved in the resolution of inflammation and wound healing; however, it is extremely unstable. Thus, to preserve its biological activities and confer stability, we encapsulated LXA(4) in poly-lactic-co-glycolic acid (PLGA) microparticles (LXA(4)-MS) and assessed its application in treating dorsal rat skin lesions. Ulcers were sealed with fibrin adhesive and treated with either LXA(4)-MS, unloaded microparticles (Un-MS), soluble LXA(4), or PBS/glue (vehicle). All groups were compared at 0, 2, 7, and 14 days post-lesions. Our results revealed that LXA(4)-MS accelerated wound healing from day 7 and reduced initial ulcer diameters by 80%. Soluble LXA(4), Un-MS, or PBS closed wounds by 60%, 45%, and 39%, respectively. LXA(4)-MS reduced IL-1 beta and TNF-alpha, but increased TGF-beta, collagen deposition, and the number of blood vessels. Compared to other treatments, LXA(4)-MS reduced inflammatory cell numbers, myeloperoxidase (MPO) concentration, and metalloproteinase- 8 (MMP8) mRNA in scar tissue, indicating decreased neutrophil chemotaxis. In addition, LXA(4)-MS treatment increased macrophages and IL-4, suggesting a positive impact on wound healing. Finally, we demonstrated that WRW4, a selective LXA(4) receptor (ALX) antagonist, reversed healing by 50%, indicating that LXA(4) must interact with ALX to induce wound healing. Our results show that LXA(4)-MS could be used as a pharmaceutical formulation for the treatment of skin ulcers. (AU)

FAPESP's process: 14/07125-6 - New functional aspects of eicosanoids
Grantee:Lúcia Helena Faccioli
Support type: Research Projects - Thematic Grants